Minprostin E2 (Dinoprostone)

Dinoprostone, the active ingredient in Minprostin E2, is a prostaglandin E2 analog presented as a vaginal formulation (strength not disclosed) for vaginal use. It promotes cervical ripening and stimulates uterine contractions in pregnant women when labor induction or termination is indicated.

GNH USA supplies Minprostin E2 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dinoprostone is used in obstetrics to facilitate physiological changes in the cervix and uterus.

Cervical ripening: softens and dilates the cervix to prepare for labor or procedures. Induction of labor: initiates uterine contractions to start the birthing process. Medical termination of pregnancy: promotes uterine activity to assist in termination procedures.

Dinoprostone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Vaginal irritation or discharge. - Nausea or vomiting. - Diarrhea. - Fever or chills. - Headache. - Uterine hyperstimulation.

Serious or Rare Side Effects: - Uterine rupture. - Severe hemorrhage. - Fetal distress. - Allergic anaphylaxis. - Pulmonary edema. - Cardiac arrhythmia.

Before using Dinoprostone, consider the following safety measures.

Avoid use in: active vaginal bleeding, prior uterine surgery, or known hypersensitivity to prostaglandins. Monitor fetal heart rate: continuous monitoring is recommended during administration. Assess uterine activity: watch for signs of hyperstimulation. Limit repeat dosing: follow prescriber guidance to reduce risk of complications. Educate patient: inform about possible side effects and when to seek medical help. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Dinoprostone can interact with other agents that affect uterine activity or prostaglandin pathways.

Major Interactions (Avoid): - Oxytocin: combined use may cause excessive uterine contractions. - Misoprostol: additive prostaglandin effects increase risk of hyperstimulation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt intended uterine response.

Moderate Interactions (Monitor Closely): - Magnesium sulfate: may reduce uterine contractility, requiring dose adjustment. - Tocolytic agents (e.g., nifedipine): may counteract Dinoprostone’s effect. - Antihypertensives: monitor blood pressure as uterine changes can affect hemodynamics.